COMMUNIQUÉS West-GlobeNewswire

Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
13/03/2024
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024 Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and [...]
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13/03/2024
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN [...]
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
13/03/2024
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE MASITINIB DÉMONTRE SA [...]
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13/03/2024
AGAMREE ® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for Patients Aged Two Years [...]
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
13/03/2024
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared [...]
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
13/03/2024
Elimination of Remaining Debt to Perceptive Advisors Leaves the Company’s Balance Sheet Debt Free PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a [...]
Atsena Therapeutics Announces Initiation of Dosing in Second Cohort of Phase I/II Clinical Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
13/03/2024
Subretinal injection of ATSN-201 was well tolerated in all patients in first cohort with no serious adverse events reported Enrollment is ongoing in first clinical trial utilizing AAV.SPR, the company’s novel spreading [...]
Vanqua Bio to Present at the Stifel 2024 CNS Days Conference
13/03/2024
CHICAGO, March 13, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that [...]
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
13/03/2024
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
13/03/2024
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiat ing Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP [...]
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
13/03/2024
Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic- [...]
HOOPP delivers 9.38% return in 2023: success bolstered by strong Canadian portfolio
13/03/2024
TORONTO, March 13, 2024 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan (HOOPP) announced today that it delivered a 9.38% return in 2023, bringing its net assets to $112.6 billion, up from $103.7 billion at [...]
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
13/03/2024
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will [...]
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
13/03/2024
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of [...]
Antheia and Olon Continue Partnership for Biomanufacturing Antheia’s Pipeline of KSMs and APIs for Essential Medicines
13/03/2024
Olon to support Antheia’s continued scale up and commercialization of early products MENLO PARK, Calif. and MILAN, Italy, March 13, 2024 (GLOBE NEWSWIRE) -- Antheia , the pharmaceutical ingredient manufacturer [...]
Appointment of new CEO
13/03/2024
ANNOUNCEMENT NO. 255 (Changed category - Inside information) Appointment of new CEO The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of [...]
Appointment of new CEO
13/03/2024
ANNOUNCEMENT NO. 254 Appointment of new CEO The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of today. The decision is based on the [...]
Faron’s Financial Statement Release January 1 to December 31, 2023
13/03/2024
TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. ("Faron" or "the Company") (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers [...]
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
13/03/2024
Press Release Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 Focusing resources on the clinical development of Nicox’s lead program NCX 470 in glaucoma NCX 470 [...]

Pages